Company Intelligence Profile
Premas Life Sciences Private Limited
Premas Life Sciences Pvt Ltd (founded/incorporated 2011, per official site marketing material sometimes traces roots to 2005) is a Delhi-based life-sciences distribution and technology-partner company serving India's research and clinical-diagnostics community.
Last updated 6 September 2026
Premas Life Sciences Private Limited is a Delhi-based company specializing in the distribution and technology partnership for life sciences, serving the Indian research and clinical diagnostics sectors. As of FY2025, the company reported revenues between Rs 309.66 to 310 Cr, with a near debt-free financial structure and a substantial partnership with Illumina spanning over 12 years.
AI-generated summary from public filings and may contain errors. Verify against the detailed sections below.
See what AICA knows about Premas Life Sciences
Deeper analysis, financial signals and peer comparisons.
Company Identity
| Registered name | Premas Life Sciences Private Limited |
|---|---|
| CIN | U51909DL2011PTC217592 |
| PAN | AAGCP0079F |
| Status |
|
| Listing | Unlisted (private limited company) |
| Incorporated | 15 April 2011 |
| ROC | RoC-Delhi |
| Sector (NIC) |
|
| Registered address | Second Floor, E-49/5, Okhla Industrial Estate, Phase-II, New Delhi, Delhi - 110020 |
| Authorized capital | Rs 30,00,00,000 (Rs 30 Cr) |
| Paid-up capital |
|
Business Overview
- Premas Life Sciences Pvt Ltd (founded/incorporated 2011, per official site marketing material sometimes traces roots to 2005) is a Delhi-based life-sciences distribution and technology-partner company serving India's research and clinical-diagnostics community
- It distributes advanced instruments and consumables across Genomics (Illumina sequencing platforms — MiSeq i100, NovaSeq series; library prep kits; Covaris), Proteomics (Olink Signature biomarker discovery), and Cell Analysis (Cytek Aurora spectral flow cytometry, SphereBio Cyto-Mine single-cell platforms), serving human health, agriculture, biopharma, environment, forensics and energy applications
- Represents 15+ global technology brands (including long-standing ~12+ year partnership with Illumina per CRISIL rationale) with 700+ installations across India, 85-101 employees including 20+ PhD-qualified staff, and 260+ research collaborations
Directors
| Name | DIN | Role | Appointed |
|---|---|---|---|
| Praveen Kumar Gupta | 03468769 | Managing Director | 15 Apr 2011 |
| Debjit Patra | 00008935 | Director | 20 Mar 2016 |
| Avijit Das | 00398852 | Director | 15 Apr 2011 |
Financials
Premas Life Sciences reported approximately Rs 310 Cr in revenue for FY2025, experiencing a slight decline of about 2% year-over-year, with a net worth of around Rs 160 Cr as of FY2023. The company maintains a strong financial position with near debt-free status and robust interest coverage.
- Standalone figures (entity is unlisted, files standalone accounts)
- Revenue trend: FY2022 ~Rs 328.01 Cr
- FY2023 ~Rs 256.3 Cr (CRISIL rationale — reflects normalization post-COVID, ~12% underlying growth ex-pandemic sales)
- FY2024 per search-snippet described as +20.37% net-sales growth and +23.63% total-assets growth YoY
- FY2025 (year ended 31 Mar 2025) revenue ~Rs 309.66-310 Cr, down ~2% YoY. Net worth: ~Rs 160 Cr as of FY2023 (CRISIL rationale)
- Gearing: 0.05x (near debt-free on a net basis) as of FY2023 (CRISIL)
- Interest coverage 34.8x, net cash accrual-to-debt 3.9x (FY2023, CRISIL)
- EBITDA/PAT absolute figures: not obtained
- 3-year revenue CAGR ~43% per CRISIL (to FY2023); more recent-period CAGR figures from search snippets show revenue CAGR -2% and EBITDA CAGR +2% (1-year, to FY2025) — treat as partial/unverified single-source
- Total employees ~88-101 (EPFO/company site, FY2024-25)
Funding
- No institutional/VC/PE funding rounds identified for Premas Life Sciences Private Limited — company appears to be entirely promoter/founder funded and bank-debt financed
- Caution: a similarly-named but distinct entity, "Premas Biotech Private Limited" (a biopharma/vaccine-tech company, different CIN), has raised ~$2.68M in VC funding per Crunchbase/PitchBook/Tracxn — this funding must NOT be attributed to Premas Life Sciences (entity-confusion trap flagged and avoided)
In the News
Uncoded by Premas Life Sciences Marks Two Years of Building India`s Genomics Future
Mid-Day · 2 months ago
Premas Life Sciences And Uncoded Advocate Genetics-Enabled Innovation For Glaucoma Care At GENE-SIGHT 2026
Outlook India · 3 months ago
Headlines about Premas Life Sciences Private Limited reported by third-party publications. Recur Club does not author or endorse this coverage. Last checked 9/6/2026.
Source: Google News aggregated headlines
Charges/Loans
- Total open charges: ~Rs 132 Cr. Key charge-holders: HDFC Bank Limited — Rs 80 Cr, registered 29 Nov 2021, Open
- Others — Rs 27 Cr, registered 22 Dec 2021, Open
- Citibank N.A. — Rs 25 Cr, registered 14 Mar 2019, Open
- Satisfied charges: Rs 0 reported
Credit Ratings
- CRISIL Ratings: Long-term "CRISIL BBB+/Stable" (reaffirmed)
- Short-term "CRISIL A2" (reaffirmed)
- Enhanced bank facilities from Rs 43 Cr to Rs 78 Cr at the time
- Facility breakdown: Cash Credit ~Rs 59 Cr (across three lenders), Bank Guarantees Rs 8 Cr, Letter of Credit Rs 10 Cr, proposed fund-based limits Rs 1 Cr. No ICRA or CARE rating found for this entity
Competitors
Frequently Asked Questions
What does Premas Life Sciences Private Limited do?
What is the CIN of Premas Life Sciences Private Limited?
Where is Premas Life Sciences Private Limited registered?
When was Premas Life Sciences Private Limited incorporated?
Recur Market
Which lenders fit a company like Premas Life Sciences Private Limited?
Answer a few questions about your business and see which banks and NBFCs match, with indicative rates.
Explore on Recur Club
More from Recur Club
Looking for business funding?
Recur Club is India's largest AI-native debt platform - working capital, term loans and structured debt from 150+ lending partners, without diluting equity.